LY233053: a structurally novel, potent and selective competitive N-methyl-D-aspartate receptor antagonist.
Ornstein
P L
PL
Lilly Research Labs, Eli Lilly and Co., Indianapolis, IN 46285.
Schoepp
D D
DD
Leander
J D
JD
Wong
T
T
Zimmerman
D M
DM
Lodge
D
D
D000818:Animals; D001667:Binding, Competitive; D001921:Brain / Q000166:cytology / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D007700:Kinetics; D051379:Mice; D016202:N-Methylaspartate / Q000633:toxicity; D009474:Neurons / Q000187:drug effects / Q000502:physiology; D010875:Pipecolic Acids / Q000378:metabolism / Q000494:pharmacology*; D051381:Rats; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors* / Q000378:metabolism; D012640:Seizures / Q000139:chemically induced / Q000188:drug therapy; D013777:Tetrazoles / Q000378:metabolism / Q000494:pharmacology*
D010875:Pipecolic Acids; D016194:Receptors, N-Methyl-D-Aspartate; D013777:Tetrazoles; C066685:LY 233053; D016202:N-Methylaspartate